Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by First Financial Bank Trust Division

First Financial Bank Trust Division lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 77,172 shares of the biopharmaceutical company’s stock after selling 2,313 shares during the quarter. First Financial Bank Trust Division’s holdings in Gilead Sciences were worth $6,470,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Centaurus Financial Inc. increased its holdings in Gilead Sciences by 12.4% in the second quarter. Centaurus Financial Inc. now owns 4,798 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 529 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Gilead Sciences in the second quarter valued at $7,847,000. Verity & Verity LLC grew its holdings in shares of Gilead Sciences by 11.1% during the second quarter. Verity & Verity LLC now owns 345,695 shares of the biopharmaceutical company’s stock worth $23,718,000 after purchasing an additional 34,482 shares during the last quarter. Newbridge Financial Services Group Inc. grew its holdings in shares of Gilead Sciences by 144.6% during the second quarter. Newbridge Financial Services Group Inc. now owns 4,165 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 2,462 shares during the last quarter. Finally, Lazari Capital Management Inc. grew its holdings in shares of Gilead Sciences by 11.9% during the second quarter. Lazari Capital Management Inc. now owns 22,995 shares of the biopharmaceutical company’s stock worth $1,578,000 after purchasing an additional 2,448 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The disclosure for this sale can be found here. In the last three months, insiders sold 36,847 shares of company stock worth $3,033,340. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on GILD shares. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a report on Monday, July 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 price objective on shares of Gilead Sciences in a report on Monday, September 16th. BMO Capital Markets raised their price objective on Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Twelve equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $82.06.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $84.74 on Thursday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The company has a market cap of $105.57 billion, a P/E ratio of 235.39, a PEG ratio of 2.91 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The company has a 50-day moving average price of $78.76 and a 200 day moving average price of $71.76.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Research analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.63%. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.